Developer docs
API playgroundTry for free, no card

Search company profiles

cypre.com

Full company profile

uuid005nxsr

Namestring
cypre.com
Legal namestring
Cypre, Inc.
Websiteurl
cypre.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Cypre, Inc. is a privately held biotechnology company headquartered in San Francisco, California that develops and commercializes 3D tumor organoid models for preclinical oncology drug discovery. The company's core platform is built on proprietary VersaGel® hydrogel technology — a tunable extracellular matrix that enables the cultivation of patient-derived tumor cells while preserving oncogenic features — and the trademarked Symphony® platform component used in conjunction with it. The architecture is a three-tiered model integrating a genomically annotated patient-derived tumor core, a stromal layer of human fibroblasts with controlled ECM density, and phenotypic immune readouts incorporating T cells, macrophages, NK cells, and B cells. The platform supports high-content screening across 30+ (and now 42 automated) PDX models spanning lung, colon, pancreatic, renal, melanoma, brain, blood, stomach, and bladder cancers, with multi-omic analytics combining high-content imaging, multiplex cytokine profiling, flow cytometry, and RNA-seq.

Cypre monetizes the platform through two distinct engagement models: (1) Translational Research Services, which delivers project-based, IND-ready preclinical data packages for lead candidate evaluation ahead of IND-enabling studies, with typical 30-60 day turnarounds; and (2) Drug Discovery Partnerships, structured as selective multi-target or multi-year strategic collaborations designed to drive candidates to IND-enabling studies within two years. Pricing is not publicly disclosed and is contract-based on scope and complexity. Go-to-market is enterprise field sales into pharmaceutical and biotechnology customers, supplemented by academic collaborations, with marketing centered on industry conferences (AACR, SITC, BIO Partnering, JPM Healthcare Conference), peer-reviewed publications, webinars (notably with Charles River Laboratories), and thought leadership around NAMs and FDA 2025 animal-testing reduction guidance.

The company was founded by Kolin C. Hribar, PhD (CEO), and operates with a small specialist team spanning biology, operations, engineering, and data. Strategic assets include a core partnership with Charles River Laboratories (formed January 2021) integrating Cypre's organoid platform with CRL's PDX compendium, peer-reviewed validation in the CELLS journal (April 2023), and a scientific advisory board featuring former senior R&D leaders from Nkarta, Eli Lilly, Gilead, Dendreon, Takeda, XOMA, and Abgenix. No institutional venture capital funding rounds have been disclosed.

Short descriptiontext

Cypre is a San Francisco-based biotech that builds 3D tumor organoid models on proprietary VersaGel® hydrogel technology to deliver preclinical efficacy, mechanism-of-action, and biomarker data for pharmaceutical and biotechnology oncology drug developers.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D tumor organoid models, tumor microenvironment platform, preclinical oncology services, hydrogel drug screening, immuno-oncology assays
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Preclinical Oncology Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Translational Research Services
TypeProfessional Services
Description

Project-based services for rigorous evaluation of lead candidates at preclinical stage prior to IND-enabling studies. Generates IND-ready data packages for regulatory submissions.

cypre.com
2Drug Discovery Partnerships
TypeManaged Services
Description

Selective multi-target or multi-year strategic partnerships spanning target identification, lead development and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years.

cypre.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cypre provides a proprietary 3D tumor organoid platform built on VersaGel hydrogel technology that recreates the human tumor microenvironment with integrated tumor, stromal, and immune compartments. The company sells Translational Research Services for preclinical evaluation of lead candidates prior to IND-enabling studies, and Drug Discovery Partnerships structured as multi-target or multi-year collaborations spanning target identification, lead development, and candidate selection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30-60 day turnaround for translational data packages
+2 more records
Product overview1 text field

Cypre offers a unified 3D tumor organoid platform centered on its proprietary VersaGel® hydrogel technology and Symphony® components. The platform integrates patient-derived tumor cells, stromal fibroblasts, and immune components (T cells, NK cells, macrophages, B cells) within a tunable extracellular matrix to recreate the human tumor microenvironment. Core offerings include the Cypre 3D Tumor Organoid Platform for mechanism of action studies and biomarker discovery, supplemented by Translational Research Services and Drug Discovery Partnerships. The platform supports therapeutic programs from target validation through IND-enabling studies across multiple tumor indications including lung, colon, pancreatic, renal, melanoma, brain, blood, and stomach cancers.

Product and service3 records
1Cypre 3D Tumor Organoid Platform
CategoryCore Platform
Description

Proprietary 3D tumor model platform that recreates the tumor-stromal-immune microenvironment to support therapeutic development through IND. Built for mechanism of action studies, biomarker discovery, and predictive preclinical data with integrated tumor, stromal, and immune components. Offered to pharmaceutical and biotechnology sponsors.

2Translational Research Services
CategoryService
Description

Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. Generates IND-ready data packages to support decision-making and discussions with regulatory agencies. Offered to pharmaceutical and biotechnology sponsors.

3Drug Discovery Partnerships
CategoryService
Description

Selective multi-target or multi-year partnership framework spanning target identification, lead development, and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years using Cypre's human-relevant data at each stage. Offered to pharmaceutical and biotechnology sponsors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-28
Description

Cypre and Charles River announced a strategic partnership to leverage Cypre's 3D Tumor Model Platform with Charles River's genomically annotated and extensively characterized PDX Tumor Model Compendium. The partnership enables end-to-end oncology discovery capabilities, combining Cypre's 3D organoid platform with CRL's tumor model collection for in vitro pharmacology and drug screening prior to IND. The collaboration has generated joint publications, conference presentations, and integrated service offerings for cancer drug discovery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Cellesce
TypeEmerging player
Description

Develops scalable organoid expansion and assay platforms for drug discovery. Comparable as an emerging 3D organoid vendor focused on industrial-scale production of tumor and tissue models for preclinical research.

TypeBroad incumbent
Description

Supplies reagents, cytokines, and 3D cell culture tools used in tumor organoid and immuno-oncology workflows. Comparable as an incumbent enabling competitor in the same translational research ecosystem, with overlapping customers in pharma and academic oncology.

TypeDirect peer
Description

Provider of patient-derived xenograft (PDX) models and organoid-based preclinical oncology services. Directly comparable to Cypre as a competing translational research platform selling 3D in vitro and in vivo oncology models to the same pharma/biotech customers.

TypeEmerging player
Description

Provides iPSC-derived cell models and organoid platforms for disease modeling and drug discovery. Comparable to Cypre as a human-relevant in vitro model vendor serving preclinical translational research, particularly in oncology and metabolic disease.

TypeDirect peer
Description

Developer of 3D in vitro microtissue and organoid platforms used for drug discovery and toxicity testing. Directly competes with Cypre's 3D tumor organoid services in oncology and broader preclinical applications.

TypeDirect peer
Description

Supplies 3D cell culture and organoid imaging platforms (e.g., high-content imaging systems) used by pharma and biotech for tumor model screening. Comparable to Cypre in enabling high-content, 3D tumor biology readouts for translational drug discovery.

TypeBroad incumbent
Description

Global CRO offering a broad portfolio of oncology discovery and safety services, including a PDX Tumor Model Compendium that is co-offered with Cypre's platform. Acts both as Cypre's primary distribution partner and as a broader incumbent competing for the same translational research budgets.

TypeEmerging player
Description

Supplies organoid culture kits, media, and related reagents for 3D in vitro tumor modeling. Comparable to Cypre as an enabling supplier in the same preclinical oncology workflow, with growing overlap in tumor organoid product offerings.

TypeBroad incumbent
Description

Life sciences tools giant offering cell culture, organoid reagents, and preclinical services through its Patheon and PPD CRO arms. Comparable as a broad incumbent that supplies enabling products and competing services across the oncology translational research value chain.

TypeOthers
Description

Large oncology drug developer and a named past collaborator with Cypre (joint 2019 minisymposium on immune exclusion tumor models). Comparable as a strategic buyer of 3D tumor microenvironment services and a potential anchor customer/partner for translational research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

cypre.com

Preclinical Oncology Servicescypre.com

Cypre is a San Francisco-based biotech that builds 3D tumor organoid models on proprietary VersaGel® hydrogel technology to deliver preclinical efficacy, mechanism-of-action, and biomarker data for pharmaceutical and biotechnology oncology drug developers.

What cypre.com does

Cypre, Inc. is a privately held biotechnology company headquartered in San Francisco, California that develops and commercializes 3D tumor organoid models for preclinical oncology drug discovery. The company's core platform is built on proprietary VersaGel® hydrogel technology — a tunable extracellular matrix that enables the cultivation of patient-derived tumor cells while preserving oncogenic features — and the trademarked Symphony® platform component used in conjunction with it. The architecture is a three-tiered model integrating a genomically annotated patient-derived tumor core, a stromal layer of human fibroblasts with controlled ECM density, and phenotypic immune readouts incorporating T cells, macrophages, NK cells, and B cells. The platform supports high-content screening across 30+ (and now 42 automated) PDX models spanning lung, colon, pancreatic, renal, melanoma, brain, blood, stomach, and bladder cancers, with multi-omic analytics combining high-content imaging, multiplex cytokine profiling, flow cytometry, and RNA-seq.

Cypre monetizes the platform through two distinct engagement models: (1) Translational Research Services, which delivers project-based, IND-ready preclinical data packages for lead candidate evaluation ahead of IND-enabling studies, with typical 30-60 day turnarounds; and (2) Drug Discovery Partnerships, structured as selective multi-target or multi-year strategic collaborations designed to drive candidates to IND-enabling studies within two years. Pricing is not publicly disclosed and is contract-based on scope and complexity. Go-to-market is enterprise field sales into pharmaceutical and biotechnology customers, supplemented by academic collaborations, with marketing centered on industry conferences (AACR, SITC, BIO Partnering, JPM Healthcare Conference), peer-reviewed publications, webinars (notably with Charles River Laboratories), and thought leadership around NAMs and FDA 2025 animal-testing reduction guidance.

The company was founded by Kolin C. Hribar, PhD (CEO), and operates with a small specialist team spanning biology, operations, engineering, and data. Strategic assets include a core partnership with Charles River Laboratories (formed January 2021) integrating Cypre's organoid platform with CRL's PDX compendium, peer-reviewed validation in the CELLS journal (April 2023), and a scientific advisory board featuring former senior R&D leaders from Nkarta, Eli Lilly, Gilead, Dendreon, Takeda, XOMA, and Abgenix. No institutional venture capital funding rounds have been disclosed.

cypre.com firmographics

Firmographics
Name
cypre.com
Legal name
Cypre, Inc.
Website
https://cypre.com
Company type
Private
Operating status
Operating
Short description
Cypre is a San Francisco-based biotech that builds 3D tumor organoid models on proprietary VersaGel® hydrogel technology to deliver preclinical efficacy, mechanism-of-action, and biomarker data for pharmaceutical and biotechnology oncology drug developers.
Ownership category
akta.pro rank

cypre.com industry classification

Industry
Product category
Preclinical Oncology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • 3D tumor organoid models
  • Tumor microenvironment platform
  • Preclinical oncology services
  • Hydrogel drug screening
  • Immuno-oncology assays

Where cypre.com is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

cypre.com business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Translational Research Services: Project-based services for rigorous evaluation of lead candidates at preclinical stage prior to IND-enabling studies. Generates IND-ready data packages for regulatory submissions.
  2. Drug Discovery Partnerships: Selective multi-target or multi-year strategic partnerships spanning target identification, lead development and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

cypre.com product offering

Product offering

Core offering

Cypre provides a proprietary 3D tumor organoid platform built on VersaGel hydrogel technology that recreates the human tumor microenvironment with integrated tumor, stromal, and immune compartments. The company sells Translational Research Services for preclinical evaluation of lead candidates prior to IND-enabling studies, and Drug Discovery Partnerships structured as multi-target or multi-year collaborations spanning target identification, lead development, and candidate selection.

Product overview

Cypre offers a unified 3D tumor organoid platform centered on its proprietary VersaGel® hydrogel technology and Symphony® components. The platform integrates patient-derived tumor cells, stromal fibroblasts, and immune components (T cells, NK cells, macrophages, B cells) within a tunable extracellular matrix to recreate the human tumor microenvironment. Core offerings include the Cypre 3D Tumor Organoid Platform for mechanism of action studies and biomarker discovery, supplemented by Translational Research Services and Drug Discovery Partnerships. The platform supports therapeutic programs from target validation through IND-enabling studies across multiple tumor indications including lung, colon, pancreatic, renal, melanoma, brain, blood, and stomach cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cypre 3D Tumor Organoid Platform Proprietary 3D tumor model platform that recreates the tumor-stromal-immune microenvironment to support therapeutic development through IND. Built for mechanism of action studies, biomarker discovery, and predictive preclinical data with integrated tumor, stromal, and immune components. Offered to pharmaceutical and biotechnology sponsors.
  • Translational Research Services Rigorous evaluation of lead candidates at the preclinical stage prior to IND-enabling studies. Generates IND-ready data packages to support decision-making and discussions with regulatory agencies. Offered to pharmaceutical and biotechnology sponsors.
  • Drug Discovery Partnerships Selective multi-target or multi-year partnership framework spanning target identification, lead development, and candidate selection. Designed to drive lead candidates to IND-enabling studies within two years using Cypre's human-relevant data at each stage. Offered to pharmaceutical and biotechnology sponsors.

Quantifiable outcome

  • 30-60 day turnaround for translational data packages
  • +2 more outcomes

Companies that use cypre.com

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

cypre.com technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

cypre.com partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Charles River LaboratoriescoreStrategic or Co-development Partner · 28 January 2021Cypre and Charles River announced a strategic partnership to leverage Cypre's 3D Tumor Model Platform with Charles River's genomically annotated and extensively characterized PDX Tumor Model Compendium. The partnership enables end-to-end oncology discovery capabilities, combining Cypre's 3D organoid platform with CRL's tumor model collection for in vitro pharmacology and drug screening prior to IND. The collaboration has generated joint publications, conference presentations, and integrated service offerings for cancer drug discovery.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

cypre.com competitors and assessment

Company assessment

Emerging players

  • Cellesce: Develops scalable organoid expansion and assay platforms for drug discovery. Comparable as an emerging 3D organoid vendor focused on industrial-scale production of tumor and tissue models for preclinical research.
  • DefiniGEN: Provides iPSC-derived cell models and organoid platforms for disease modeling and drug discovery. Comparable to Cypre as a human-relevant in vitro model vendor serving preclinical translational research, particularly in oncology and metabolic disease.
  • STEMCELL Technologies: Supplies organoid culture kits, media, and related reagents for 3D in vitro tumor modeling. Comparable to Cypre as an enabling supplier in the same preclinical oncology workflow, with growing overlap in tumor organoid product offerings.

Broad incumbents

  • Bio-Techne: Supplies reagents, cytokines, and 3D cell culture tools used in tumor organoid and immuno-oncology workflows. Comparable as an incumbent enabling competitor in the same translational research ecosystem, with overlapping customers in pharma and academic oncology.
  • Charles River Laboratories: Global CRO offering a broad portfolio of oncology discovery and safety services, including a PDX Tumor Model Compendium that is co-offered with Cypre's platform. Acts both as Cypre's primary distribution partner and as a broader incumbent competing for the same translational research budgets.
  • Thermo Fisher Scientific: Life sciences tools giant offering cell culture, organoid reagents, and preclinical services through its Patheon and PPD CRO arms. Comparable as a broad incumbent that supplies enabling products and competing services across the oncology translational research value chain.

Direct peers

  • Crown Bioscience: Provider of patient-derived xenograft (PDX) models and organoid-based preclinical oncology services. Directly comparable to Cypre as a competing translational research platform selling 3D in vitro and in vivo oncology models to the same pharma/biotech customers.
  • InSphero: Developer of 3D in vitro microtissue and organoid platforms used for drug discovery and toxicity testing. Directly competes with Cypre's 3D tumor organoid services in oncology and broader preclinical applications.
  • Molecular Devices: Supplies 3D cell culture and organoid imaging platforms (e.g., high-content imaging systems) used by pharma and biotech for tumor model screening. Comparable to Cypre in enabling high-content, 3D tumor biology readouts for translational drug discovery.

Others

  • Genentech (Roche): Large oncology drug developer and a named past collaborator with Cypre (joint 2019 minisymposium on immune exclusion tumor models). Comparable as a strategic buyer of 3D tumor microenvironment services and a potential anchor customer/partner for translational research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

cypre.com financial estimates

Financial estimate

Revenue estimate

Valuation estimate

cypre.com leadership team

Management profile

Number of profiles

Profiles12 records

cypre.com funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

cypre.com M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cypre.com

What does cypre.com do?

Cypre provides a proprietary 3D tumor organoid platform built on VersaGel hydrogel technology that recreates the human tumor microenvironment with integrated tumor, stromal, and immune compartments. The company sells Translational Research Services for preclinical evaluation of lead candidates prior to IND-enabling studies, and Drug Discovery Partnerships structured as multi-target or multi-year collaborations spanning target identification, lead development, and candidate selection.

Is cypre.com a public or private company?

cypre.com is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was cypre.com founded?

cypre.com was founded in -1.

Where is cypre.com based?

cypre.com is headquartered in San Francisco, United States, in the North America region.

How does cypre.com make money?

Two revenue lines are on record. Translational Research Services are the primary driver. The others are drug Discovery Partnerships.

Who are cypre.com's main competitors?

Emerging players on record are Cellesce, DefiniGEN and STEMCELL Technologies. Broad incumbents are Bio-Techne, Charles River Laboratories and Thermo Fisher Scientific. Direct peers are Crown Bioscience, InSphero and Molecular Devices. Genentech (Roche) is listed as an others.

Does cypre.com have an API?

No public API is recorded for cypre.com.

What industry is cypre.com in?

cypre.com's product category is Preclinical Oncology Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals